ABSTRACT
The cancer stem cell model was described for hematologic malignancies in 1997 and since then evidence has emerged to support it for many solid tumors as well, including colon cancer. This model proposes that certain cells within the tumor mass are pluripotent and capable of self-renewal and have an enhanced ability to initiate distant metastasis. The cancer stem cell model has important implications for cancer treatment, since most current therapies target actively proliferating cells and may not be effective against the cancer stem cells that are responsible for recurrence. In recent years great progress has been made in identifying markers of both normal and malignant colon stem cells. Proteins proposed as colon cancer stem cell markers include CD133, CD44, CD166, ALDH1A1, Lgr5, and several others. In this review we consider the evidence for these proteins as colon cancer stem cell markers and as prognostic indicators of colon cancer survival. Additionally, we discuss potential functions of these proteins and the implications this may have for development of therapies that target colon cancer stem cells.
INTRODUCTION
Colon cancer is the third most common cancer in the United States and the second leading cause of cancer deaths with an estimated 150,000 newly diagnosed cases and 50,000 deaths in 2008 (1) . Most deaths from colon cancer occur from metastasis of the cancer to other tissues, most commonly the liver (2) . Over the last decade the cancer stem cell (CSC) model, also known as the hierarchy model, has become increasingly accepted as an explanation for cancer spread and recurrence (3) (4) (5) . Evidence for this model was first described for hematologic malignancies (6) , and in recent years experimental support for it has emerged for many solid tumors as well. This model posits that a small subpopulation of tumor cells have an enhanced potency and ability to initiate distant metastases compared to the rest of the tumor cells, are capable of self-renewal, form metastatic tumors of heterogeneous cell types that resemble the primary tumor, and are more resistant to therapy (3, 5) . The stochastic model of cancer progression, in contrast, holds that each cell within the tumor mass is equally capable of initiating distant metastases (3) (4) (5) . In colon, the precise position of stem cells at the bottom of the crypt has not been determined. Additionally, Bmi1+ stem cells were detected in mouse small intestine but not mouse colon (13) . Dotted line for CD133 expression in villus cells indicates differing results concerning its expression in these cells. The precise position of the cells in the bottom part of the crypt that express ALDH1A1 and CD166 has not been determined. Musashi-1 is not detected in Paneth cells in the mouse small intestine (103) . Additional details are described in the text.
The biology of the normal intestinal epithelium has been described in several recent reviews (7) (8) (9) (10) and is beyond the focus of this article. Before discussing colon CSC markers, however, it is necessary to briefly describe what is known of normal small intestinal and colon stem cells. In both the mouse small intestine and colon, the stem cells lie towards the bottom of the crypt in the proliferative zone, and are responsible for generating all epithelial cell types along the crypt-villus axis. It is thought that 4 to 6 stem cells are present in each crypt (11) . In the small intestine two stem cell populations have been identified (Figure 1 ), the crypt base columnar cells, marked by expression of the G-protein receptor Lgr5 and positioned just above the Paneth cells at the bottom of the crypt (12) , and cells at the +4 position from the bottom of the crypt (11), which recent research has shown are marked by expression of the polycomb group gene Bmi1 (13) . Both cell types have been demonstrated to fulfill the criteria for stem cells (pluripotency and self-renewal capacity), though it is unclear at this point whether they represent the same or distinct cell populations. In the colon the precise position of the stem cells has not been determined, though they are known to lie at or near the bottom of the crypt. Colon stem cells are also marked by Lgr5 expression (12) . In mice, stem cells marked by Bmi1 expression are only present in the small intestine (13) .
A stem cell origin for colon cancers is suggested by the observation of proliferating multipotent cell expansion at the intestinal epithelial crypt base that occurs during adenoma development in familial adenomatous polyposis (FAP) patients (14) , who have mutations in the adenomatous polyposis coli (APC) gene that predispose them to gastrointestinal polyps and cancer. It has also long been known from histological examination of human colon adenocarcinomas that they contain multiple intestinal cell types of varying degrees of differentiation (15) (16) (17) , and that single colon adenocarcinomas have variable expression of proteins such as MUC2 (18) , neuroendocrine markers (19) , and villin (20) . The stochastic and CSC models differ in explaining how this arises. The stochastic model posits that this heterogeneity results from a multiclonal origin of the tumor. The CSC model, by contrast, proposes that colon adenocarcinomas arise from a single multipotent stem cell that gives rise to tumors containing multiple cell types. It predicts that a single CSC from the original tumor is capable of initiating metastatic tumors that are histopathologically similar to the tumor of origin. It is only in the last five years, however, that experimental evidence directly demonstrating the origin of colon CSCs from normal colon stem cells has been provided and that colon CSC molecular markers have been identified.
The majority of colon cancers arise through dysfunctional regulation of the Wnt/beta-catenin pathway, either through inactivating mutations in the beta-catenin negative regulator APC or activating mutations in betacatenin. This leads to abnormal accumulation of a betacatenin/transcription factor T-cell factor 4 (Tcf4) complex in the nucleus (21, 22) , activation of the Tcf4 target c-MYC and subsequent suppression of differentiation through inhibition of p21CIP1/WAF1 expression (23). As will be discussed in more detail later, both Bmi1+ and Lgr5+ stem cell populations are capable of generating tumors in mice when beta-catenin signaling is activated specifically in these cells (12, 13) . Broadly speaking, two different approaches have been used to identify potential markers of colon CSCs. First, the molecular profile of genes activated by the beta-catenin/Tcf4 complex has led to the identification of colon CSC markers such as Lgr5 (23, 24). In the other approach, CSC markers such as CD133 (25, 26), identified from cancers of other tissues, have been tested as colon CSC markers.
Markers for human CSCs have most commonly been identified based on their ability to form tumors when subcutaneously injected in immune-compromised (usually NOD/SCID) mice. Limiting dilution of tumor cells sorted for a particular molecular marker is performed to determine the number of cells required to initiate tumor formation compared to the number of unsorted tumor cells required for tumor formation. The ability to form spheroid cultures in vitro (27) in stem cell medium has also been used to test for CSC markers. This review will focus on proposed colon CSC markers, their expression in normal colonic mucosa and colon cancers, and their utility as prognostic indicators and targets for specifically eliminating colon CSCs. CD133 mRNA or protein expression in tumors has been found in most reports to correlate with a poor prognosis. Circulating levels (35) and tumor levels (36) of CD133 mRNA are associated with lower survival. Tumor levels of CD133 mRNA also correlate with distant metastasis formation for rectal tumors (37). CD133 protein expression assessed by immunohistochemistry in a colon adenocarcinoma microarray (38) and by percentage of CD133 expressing cells (39) significantly correlated with low survival, and in a case control study high CD133 protein expression levels are correlated with liver metastasis (40). Choi et al., however, did not find that CD133 expression assessed by immunohistochemistry correlated with survival (41).
Potential functions for CD133 in colon CSCs remain to be demonstrated. Zhu et al did not observe an overt phenotype in CD133 null mice (32), and reduction of CD133 expression by siRNA in two colon cancer cell lines, Caco-2 and LoVo, did not affect invasion, proliferation, or colony formation (40). While Feng et al. found that CD133 expression inversely correlated with the degree of differentiation of colon cancer cell lines, siRNA knockdown of CD133 had no effect on differentiation (30). In two independent studies, siRNA reduction of CD133 in primary human colon tumor cells does not affect colony formation (30, 42), and one of these studies additionally demonstrated that tumorigenicity of these cells injected subcutaneously in SCID mice is not affected (42). In total, the evidence suggests that CD133 has value as a marker of colon CSCs and as an indicator of the aggressiveness of colonic tumors, but that it is not likely to be a useful therapeutic target for elimination of colon CSCs.
3.2.CD44
CD44, a receptor for the extracellular matrix protein hyaluranon, was first identified as a potential CSC marker for breast cancers (43) and is, like CD133, a transmembrane glycoprotein. Expression of CD44 is also activated by the beta-catenin/Tcf-4 complex in colon cancer cells (23). CD44 expression is confined to the crypt epithelium in non-neoplastic mucosa of Apc+/Apc1638 mice and increases with progression of cancer (44) . CD44 has many variant splice forms, and prior to its identification as a potential colon CSC marker, it had been demonstrated that expression of several CD44 splice variants correlates with colon cancer progression (45) (46) (47) (48) (49) (50) . Thus when evaluating studies examining CD44 as a potential colon CSC marker it must be taken into account that the methods employed may not distinguish between different CD44 splice variants. Dalerba et al. first identified CD44 as a potential CSC marker (51) . In this study, 2 of 5 mice developed tumors when injected with 10,000 CD44+ cells from human colon tumor cells that had been serially passaged in NOD/SCID mice, compared to 0 of 5 mice injected with CD44-cells. Though a direct comparison with tumor initiating capacity of CD133+ cells was not performed, CD133 was expressed in a larger percentage of cells than CD44, suggesting that CD44 is a more selective marker for colon CSCs. Du et al. also found that CD44 is more selective as a colon CSC marker than CD133, since as few as 1 of 100 CD44+ cells from human tumors were capable of initiating tumor formation in SCID mice. Additionally, CD44+ cells were found to have greater tumor initiating potential than CD133+ cells from the same tumor, and 24% of CD44+ cells, but only 1.8% of CD133+ cells, were capable of forming tumor spheroid holoclones (42).
Unlike CD133 (30, 42), siRNA reduction of CD44 in primary human colon cancer cells reduces colony formation and inhibits tumor formation from cells injected subcutaneously in SCID mice (42). HT29 cells transfected with CD44 siRNA also exhibit reduced colony formation and tumor formation in SCID mice (52) and reduced migration (53) . Additionally, shRNA specifically targeting the CD44v6 splice variant inhibits adenoma formation in APC Min/+ mice (54) . In normal human colon expression of CD44 is found at the crypt base where stem cells are located ( figure 1; (42) ). Patel et al. found increased expression of CD44 in normal appearing intestinal mucosa from patients with adenomatous polyps, and that increased expression of CD44 in the normal appearing tissue correlated with increasing age and the number of polyps in the patient (55) . Additionally, expression of CD44 in rat colon increased following exposure to the carcinogen dimethylhydrazine (56) , and increased expression of CD44 appears to precede K-ras and p53 gene alterations (45) , suggesting that increased expression of CD44 may be an early indicator for the presence of colon CSCs. Taken together, this evidence suggests that CD44 may be a useful therapeutic target for elimination of colon CSCs and that it is a more specific marker for colon CSCs than CD133. As noted above, however, many different splice variants of CD44 exist. Therefore, an important subject for future studies will be to determine whether colon CSCs express particular splice variants of CD44. If so, this may allow the design of targeted therapies with greater efficacy and specificity.
CD166
CD166/activated leukocyte cell adhesion molecule (ALCAM) belongs to the immunoglobulin superfamily of cell adhesion molecules, with five extracellular immunoglobulin domains, a transmembrane region and a short cytoplasmic C-terminal region. It is found at sites of cell-cell contact and is involved in both homotypic and heterotypic (to CD6) adhesion. CD166 was observed by Weichert et al. in 2004 to have increased and heterogeneous expression in colon carcinoma (57) and was first identified as a potential colon CSC marker by Dalerba et al. in 2007 (51) . While it was not examined as an individual stem cell marker in this study, sorting for CD166 in addition to CD44 or in addition to both CD44 and epithelial cell adhesion molecule (EpCAM) identified a population of colon CSCs with increased tumor initiating potential. Vermeulen et al. observed that sorting dissociated colonic adenocarcinomas for CD166 in addition to CD133 did not increase the frequency of colonosphere formation from single cells compared to sorting for CD133 alone (58), although CD166 expression is enriched in tumor spheroids derived from CD133-sorted primary colon cancer cells (59).
The function of CD166 both in normal colonic mucosa and in colon CSCs is unclear. Weichert et al.
observed expression of CD166 to be confined to a few cells at the crypt base in normal human colonic epithelium (57), while Levi et al. (56) observed similar limited expression in young rat colonic mucosa (figure 1). Knockout of CD166 in mice does not cause overt phenotypes (60) (57) . CD166 protein expression in a colonic adenocarcinoma tissue sample microarray also correlated somewhat (p=0.07) with low survival, but CD133 expression was found to be a stronger prognostic indicator of low survival in this study (61) . Notably, however, the value of CD166 as a single prognostic marker for colon CSCs is unclear, since in sorting studies of colon cancer cells it has mainly been examined in combination with other stem cell markers. Its value as a potential colon CSC therapeutic target is also not clear, since siRNA knockdown studies in colon CSC cells or colon cancerderived cell lines do not appear to have been performed.
Aldehyde dehydrogenase 1A1 (ALDH1A1)
ALDH1A1 was first identified as a marker for normal and malignant breast stem cells in 2007 by Ginestier et al. (62) , and was subsequently identified as a marker for normal and malignant colon stem cells in 2009 by Huang et al. (63) . In this study, direct comparison of ALDH1A1, CD133, and CD44 expression in normal colon cells indicated that ALDH1A1 was restricted to fewer cells at the crypt base than either CD133 or CD44 (figure 1), indicating it is a more selective marker for the least differentiated cells. Cells at the crypt base expressing ALDH1A1 were a subset of those expressing the other two markers, and in colon tumors ALDH1A1 was expressed in a smaller proportion of cells. In adenomatous crypts the proportion of cells expressing ALDH1A1 increases by fivefold (63) . Based on this and the observation that ALDH1A1+/CD44-and ALDH1A1+/CD133-cells initiate tumors in SCID mice, the authors conclude that ALDH1A1 is a selective marker for colon CSCs. Compared to selection for ALDH1A1 expression alone, combined selection for ALDH1A1 and CD133 somewhat increases the proportion of tumor initiating cells and the size of tumors, and combined selection for ALDH1A1 and CD44 does not affect the rate of tumor initiation but generates tumors of somewhat larger size (63) . The findings on ALDH1A1 expression in normal colon and colon cancer were confirmed by immunohistochemical staining of normal human colon and a tissue array of 67 colon cancers, though it should be noted that a small percentage of cancers in this study were negative for ALDH1A1 (64) . Carpentino et al. also observed an expansion of crypt cells expressing ALDH1A1 in patients with chronic colitis, an important risk factor for CRC (65).
ALDH1A1 is of particular interest because of its role in detoxifying cyclophosphamide class chemotherapeutic agents (reviewed in (66)). Thus, it is conceivable that disabling ALDH1A1 could make colon CSCs more sensitive to these drugs. It should be noted, however, that ALDH1A1 is one of 19 members of the ALDH superfamily (reviewed in (67)), at least one of which, ALDH3A1, also confers resistance to cyclophosphamide-derived drugs (68, 69) and has been detected by activity assays in colon cancers (70) . The detailed expression pattern of ALDH3A1, however, in the normal colon and in colon adenocarcinomas has not yet been characterized.
ATP binding cassette proteins
ATP binding cassette proteins (ABC) use cellular ATP to drive the transport of drugs, metabolites, and other compounds across cell membranes. This protein family consists of about 50 members, two of which, MDR1 (multi-drug resistance protein 1; also known as ABCB1 or p-glycoprotein) and ABCG2 have been identified as responsible for resistance to chemotherapeutic agents. ABCG2 was cloned from human breast cancer MCF-7 cells and demonstrated to be responsible for resistance to doxorubicin and related compounds (71) . Since that time it has been demonstrated to be capable of effluxing a wide variety of chemotherapeutic drugs (reviewed in (72) (75) . Burkert et al., however, did not find any difference in tumorigenic potential of SP and non-SP Caco-2 and HT29 cells, and also observed that expression of CD44 and CD133 was similar in SP and non-SP cells. Interestingly, ABCG2 was only expressed in less than 5% of SP cells, and expression did not differ between SP and non-SP cells, suggesting that other membrane transporters may be responsible for the SP phenotype in colon cancer cells (76) . Other methods, such as direct flow cytometry sorting for ABCG2, may need to be utilized to determine if ABCG2 is a colon CSC marker.
A direct assessment of MDR1 as a colon CSC marker has not been performed. In HT29 cells selected for CD133 expression, siRNA targeting MDR1 increases sensitivity of the cells to paclitaxel (77) , suggesting that MDR1 is present in colon CSCs. Immunohistochemical staining for MDR1 expression in ileum and colon, however, indicates that MDR1 expression may not be limited to crypt stem cells (78) . Salinomycin, recently demonstrated to specifically target breast CSCs (79), may act in part by inhibiting MDR1 function (80) . It will obviously be of great interest to determine whether colon CSCs are also sensitive to salinomycin.
Lgr5
Barker et al. identified Lgr5 (Leucine-rich Gprotein coupled receptor 5) as an intestinal epithelial stem cell marker in 2007 (12) . It is one of about eighty genes demonstrated to be a target of the Wnt-regulated transcription factor T-cell factor 4 (23, 24). Histological examination of its expression (figure 1) determined that it is present only in the small number of cycling columnar cells at the crypt base in the small intestine and colon (12, 81) Lgr5 is an orphan receptor for which the ligand and downstream G-protein effectors have not been determined (reviewed in (7)). Lgr5 null mice exhibit 100% neonatal lethality with gastrointestinal distension (86) , suggesting an essential function, but the phenotype of conditional intestinal epithelial cell Lgr5 null mice does not appear to have been determined. Thus it is not known whether Lgr5 is essential for colon CSC function, and thus possibly could be a specific colon CSC therapeutic target, or may only serve as a marker for colon CSCs.
Other potential colon CSC markers
Other proteins identified as potential colon CSC markers include CD24, beta1 integrin (CD29), EpCAM, OlfM4, Bmi1 and Musashi-1. In most cases these proteins have not been tested as single markers for selection of tumor-initiating colon CSCs in NOD/SCID mice. Low CD24 expression in combination with high CD44 expression was identified as a selection marker for breast Beta1 integrin expression is enriched in the proliferative zone of colonic crypts (figure 1), and selects for intestinal epithelial cells with enhanced clonogenic capacity as measured in a soft agar assay (88) . Disruption of beta1 integrin heterodimer interaction with extracellular matrix leads to rapid onset of apoptosis of colonic crypt cells (89) , and the alpha2 beta1 integrin ligand collagen I promotes a stem-cell like phenotype of colon cancer cell lines with increased expression of Bmi1 and CD133 (90) . Beta1 integrin expression is enriched in colonospheres derived from CD133+ primary colon tumor cells (59), but selection of primary colon cancer cells for beta1 integrin expression in addition to CD133 expression does not select for more clonogenic cells than selection for CD133 alone (58). It does not appear, however, that beta1 integrin has been tested as a single selection marker for colon CSCs.
EpCAM expression in colon adenocaracinomas was first described more than 30 years ago (91) , and overexpression of EpCAM was found in 98% of primary human colon cancers as assessed by immunohistochemical staining (92) . Colon cancer cells selected for EpCAM expression in addition to CD44 expression had greatly enhanced tumor initiating capacity compared to cells selected only for CD44. 21 of 28 mice developed tumors when injected with 200 EpCAM+/CD44+ colon cancer cells, while only 2 of 5 mice injected with 10,000 singlyselected CD44+ cells developed tumors (51) . EpCAM is cleaved by TACE and pre-senilin 2, resulting in release of the extracellular domain and release of the intracellular domain into the cytoplasm. The released extracellular domain appears to act as an autocrine stimulator of EpCAM cleavage (93) . The EpCAM intracellular domain is a coactivator of the Wnt/beta-catenin pathway through its association with the beta-catenin/Tcf4 transcriptional activation complex in the nucleus. The EpCAM intracellular domain is detectable in the nuclei of colon carcinoma cells, but not of normal cells, and siRNA knockdown increases apoptosis and decreases proliferation of HCT-8 colon cancer cells (93) . Consistent with these observations, membranous EpCAM expression is observed to be lost in budding colon cancer cells (94) . These studies indicate that EpCAM may have value as both a prognostic indicator of colon CSCs and a potential therapeutic target.
OlfM4, a member of the olfactomedin glycoprotein family, is specifically expressed in Lgr5+ stem cells in the mouse small intestine ( figure 1 ; (95)) and in both the human small intestine and colon (96) . It is expressed in a subset of cells in colorectal carcinoma as detected by immunohistochemistry (96) , and additional studies indicate it is overexpressed in colon cancer (97, 98) . Another study, while observing OlfM4 mRNA overexpression in well-differentiated colon tumors compared to normal tissue, found that expression decreased in poorly differentiated tumors (99) . Since OlfM4 is a secreted protein, it has been difficult to test it as a colon CSC marker.
The polycomb group gene Bmi1 is a marker of small intestinal stem cells at the +4 position from the crypt bottom (figure 1). As observed for Lgr5+ stem cells, the Bmi1+ cells are pluripotent, capable of self-renewal, and form adenomas when the Wnt/beta-catenin signaling pathway is activated within them (13) . Bmi1 is overexpressed in precancerous colonic lesions and is more highly overexpressed in cancerous tissues (100) . High Bmi1 expression in tumors also predicts poor survival for colon cancer patients (101) . (103) . Musashi-1 is also overexpressed in human colonic adenocarcinomas, and injection of Musashi-1 siRNA into xenografted tumors derived from HCT116 cells resulted in a greater than 75% reduction in tumor volume. Musashi-1 knockdown by siRNA also reduced proliferation, stimulated apoptosis, and caused an increase in expression of the differentiation marker p21 WAF1 in HCT116 cells (104) . This suggests Musashi-1 may have value both as a colon CSC marker and as a therapeutic target.
SUMMARY AND PERSPECTIVE
Although tremendous progress has been made in identifying the molecular characteristics of colon CSCs, there is still an urgent need for therapeutic strategies that specifically target them. Therapies targeted to the epidermal growth factor receptor and the vascular endothelial growth factor receptor have proven only marginally effective against metastatic colon cancer (105), and it is likely that complete tumor eradication will require multiple therapeutic approaches. The CSCs that appear to be responsible for cancer recurrence may lie dormant for many years (106, 107) , and thus are resistant to many current therapies that target actively proliferating cells.
Exposure of colon cancer cell lines to colon cancer chemotherapeutic agents oxaliplatin, 5-FU, or the combination of the two (FOLFOX), selects for cells that have higher CD133 expression (108, 109) . Exposure of colon CSC-derived xenografts in mice to FOLFOX, while effective at reducing tumor size, also significantly increased the proportion of CD133+ cells (110), indicating a higher percentage of the surviving cells are colon CSCs. One therapeutic approach being actively investigated is to stimulate differentiation of colon CSCs, thus making them more vulnerable to existing therapeutic agents. Salinomycin, recently identified to target breast CSCs, appears to operate in part by this mechanism (79). Among the colon CSC markers that have been identified so far, the cell surface proteins CD44 and Lgr5 appear to have potential as therapeutic targets since they are cell surface proteins with restricted expression, and both may be important to colon CSC function.
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